Comprehensive Stock Comparison
Compare YD Bio Limited Ordinary Shares (YDES) vs Cardio Diagnostics Holdings, Inc. (CDIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  CDIO | 104.5% revenue growth vs YDES's 45.8% |
| Quality / Margins |  YDES | -276.6% net margin vs CDIO's -415.2% |
| Stability / Safety | YDES | Beta 1.64 vs CDIO's 2.02, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | YDES | -29.8% vs CDIO's -62.1% |
| Efficiency (ROA) | CDIO | -74.5% ROA vs YDES's -100.8%, ROIC -222.7% vs -63.3% |
Who Each Stock Is For
Income & stability
YDESbeta 1.64
Growth exposure
CDIORev growth 104.5%, EPS growth 53.0%, 3Y rev CAGR 238.3%
Long-term compounding (10Y)
YDES-29.8% 10Y total return vs CDIO's -98.2%
Sleep-well-at-night portfolio
YDESLower volatility, beta 1.64, Low D/E 0.3%, current ratio 13.18x
Defensive / Recession hedge
YDESBeta 1.64, current ratio 13.18x
Business Model
What each company does and how it makes money
YD Bio is a clinical-stage biopharmaceutical company developing exosome-based therapeutics for cancer prevention and treatment. It generates revenue primarily through research grants and partnerships — with future income expected from drug licensing and commercialization — though it's currently in pre-revenue stages as it advances its pipeline. The company's competitive advantage lies in its proprietary exosome technology platform, which targets diseases with significant unmet medical needs.
Cardio Diagnostics develops and commercializes epigenetics-based clinical tests for cardiovascular disease risk assessment. It generates revenue primarily from sales of its Epi+Gen CHD test—a three-year symptomatic coronary heart disease risk assessment—to healthcare providers and through laboratory services. The company's moat lies in its proprietary epigenetic technology platform that offers more personalized cardiovascular risk prediction than traditional methods.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
YDES 5CDIO 0YDES5/5 metricsYDES3/3 metricsYDES5/9 metricsYDES5/6 metricsYDES2/2 metricsYDES leads in 5 of 6 categories — strongest in Financial Metrics and Valuation Metrics.
Financial Metrics (TTM)
CDIO and YDES operate at a comparable scale, with $15,782 and $0 in trailing revenue. YDES is the more profitable business, keeping -2.8% of every revenue dollar as net income compared to CDIO's -415.2%.
| Metric | YDESYD Bio Limited Or… | CDIOCardio Diagnostic… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $15,782 |
| EBITDAEarnings before interest/tax | -$3M | -$6M |
| Net IncomeAfter-tax profit | -$3M | -$7M |
| Free Cash FlowCash after capex | -$1M | -$6M |
| Gross MarginGross profit ÷ Revenue | +30.4% | -10.3% |
| Operating MarginEBIT ÷ Revenue | -2.9% | -414.2% |
| Net MarginNet income ÷ Revenue | -2.8% | -415.2% |
| FCF MarginFCF ÷ Revenue | -9.3% | -379.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -56.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -116.0% | -15.3% |
Valuation Metrics
| Metric | YDESYD Bio Limited Or… | CDIOCardio Diagnostic… |
|---|---|---|
| Market CapShares × price | $35M | $141M |
| Enterprise ValueMkt cap + debt − cash | $32M | $135M |
| Trailing P/EPrice ÷ TTM EPS | -15.09x | -0.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 68.64x | 4054.38x |
| Price / BookPrice ÷ Book value/share | 5.32x | 14.80x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
YDES delivers a -42.7% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-80 for CDIO. YDES carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CDIO's 0.10x. On the Piotroski fundamental quality scale (0–9), CDIO scores 4/9 vs YDES's 3/9, reflecting mixed financial health.
| Metric | YDESYD Bio Limited Or… | CDIOCardio Diagnostic… |
|---|---|---|
| ROE (TTM)Return on equity | -42.7% | -80.4% |
| ROA (TTM)Return on assets | -100.8% | -74.5% |
| ROICReturn on invested capital | -63.3% | -2.2% |
| ROCEReturn on capital employed | -44.1% | -123.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.10x |
| Net DebtTotal debt minus cash | -$3M | -$7M |
| Cash & Equiv.Liquid assets | $3M | $8M |
| Total DebtShort + long-term debt | $22,555 | $969,863 |
| Interest CoverageEBIT ÷ Interest expense | -1893.69x | -418.04x |
Total Returns (with DRIP)
A $10,000 investment in YDES five years ago would be worth $7,018 today (with dividends reinvested), compared to $179 for CDIO. Over the past 12 months, YDES leads with a -29.8% total return vs CDIO's -62.1%. The 3-year compound annual growth rate (CAGR) favors YDES at -11.1% vs CDIO's -68.0% — a key indicator of consistent wealth creation.
| Metric | YDESYD Bio Limited Or… | CDIOCardio Diagnostic… |
|---|---|---|
| YTD ReturnYear-to-date | -29.6% | +85.2% |
| 1-Year ReturnPast 12 months | -29.8% | -62.1% |
| 3-Year ReturnCumulative with dividends | -29.8% | -96.7% |
| 5-Year ReturnCumulative with dividends | -29.8% | -98.2% |
| 10-Year ReturnCumulative with dividends | -29.8% | -98.2% |
| CAGR (3Y)Annualised 3-year return | -11.1% | -68.0% |
Risk & Volatility
YDES is the less volatile stock with a 1.64 beta — it tends to amplify market swings less than CDIO's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. YDES currently trades 33.8% from its 52-week high vs CDIO's 30.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | YDESYD Bio Limited Or… | CDIOCardio Diagnostic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.64x | 2.02x |
| 52-Week HighHighest price in past year | $25.00 | $17.39 |
| 52-Week LowLowest price in past year | $5.30 | $0.97 |
| % of 52W HighCurrent price vs 52-week peak | +33.8% | +30.2% |
| RSI (14)Momentum oscillator 0–100 | 36.9 | 64.3 |
| Avg Volume (50D)Average daily shares traded | 40K | 3.3M |
Analyst Outlook
| Metric | YDESYD Bio Limited Or… | CDIOCardio Diagnostic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Revenue Growth — 10 Years
| Stock | 2020 | 2024 | Change |
|---|---|---|---|
| YD Bio Limited Ordi… (YDES) | $0.00 | $510360.00 | — |
| Cardio Diagnostics … (CDIO) | $0.00 | $34890.00 | — |
YD Bio Limited Ordinary Shares's revenue grew from $0M (2020) to $1M (2024) — a 0.0% CAGR. Cardio Diagnostics Holdings, Inc.'s revenue grew from $0M (2020) to $0M (2024) — a 0.0% CAGR.
Chart 2Net Margin Trend — 10 Years
| Stock | 2021 | 2024 | Change |
|---|---|---|---|
| YD Bio Limited Ordi… (YDES) | 3.9% | -2.8% | -171.4% |
| Cardio Diagnostics … (CDIO) | -688.6% | -240.3% | +65.1% |
Cardio Diagnostics Holdings, Inc.'s net margin went from -689% (2021) to -240% (2024).
Chart 3EPS Growth — 10 Years
| Stock | 2020 | 2024 | Change |
|---|---|---|---|
| YD Bio Limited Ordi… (YDES) | -0.17 | -0.56 | -229.4% |
| Cardio Diagnostics … (CDIO) | -0.06 | -9.3 | -14522.6% |
YD Bio Limited Ordinary Shares's EPS grew from $-0.17 (2020) to $-0.56 (2024). Cardio Diagnostics Holdings, Inc.'s EPS grew from $-0.06 (2020) to $-9.30 (2024).
Chart 4Free Cash Flow — 5 Years
YD Bio Limited Ordinary Shares generated $-5M FCF in 2024 (-590% vs 2021). Cardio Diagnostics Holdings, Inc. generated $-5M FCF in 2024 (-672% vs 2021).
YDES vs CDIO: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — YDES or CDIO?
Over the past 5 years, YD Bio Limited Ordinary Shares (YDES) delivered a total return of -29.8%, compared to -98.2% for Cardio Diagnostics Holdings, Inc. (CDIO). A $10,000 investment in YDES five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: YDES returned -29.8% versus CDIO's -98.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — YDES or CDIO?
By beta (market sensitivity over 5 years), YD Bio Limited Ordinary Shares (YDES) is the lower-risk stock at 1.64β versus Cardio Diagnostics Holdings, Inc.'s 2.02β — meaning CDIO is approximately 23% more volatile than YDES relative to the S&P 500. On balance sheet safety, YD Bio Limited Ordinary Shares (YDES) carries a lower debt/equity ratio of 0% versus 10% for Cardio Diagnostics Holdings, Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — YDES or CDIO?
YD Bio Limited Ordinary Shares (YDES) is the more profitable company, earning -276.6% net margin versus -240.3% for Cardio Diagnostics Holdings, Inc. — meaning it keeps -276.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: YDES leads at -286.5% versus -239.8% for CDIO. At the gross margin level — before operating expenses — CDIO leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — YDES or CDIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is YDES or CDIO better for a retirement portfolio?
For long-horizon retirement investors, YD Bio Limited Ordinary Shares (YDES) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cardio Diagnostics Holdings, Inc. (CDIO) carries a higher beta of 2.02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YDES: -29.8%, CDIO: -98.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between YDES and CDIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.